MRK vs NVDA: Which Is the Better Buy?

Side-by-side comparison of Merck & Co., Inc. and NVIDIA Corporation โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Merck & Co., Inc. ยท Healthcare
$121.42
-2.9% upside to fair value
Med Conviction Grade B
VS
NVIDIA Corporation ยท Technology
$182.08
+59.3% upside to fair value
High Conviction Grade A-
QuantHub Verdict
NVDA has more upside to fair value (+59.3%). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric MRK NVDA
Current Price $121.42 $182.08
Fair Value Estimate $118.00 $290.00
Upside to Fair Value -2.9% +59.3%
Market Cap $300.2B $4,425.5B
Forward P/E 14.0x โ€”
EV / EBITDA 11.8x 31.4x
Price / Sales 4.1x 21.0x
Price / FCF 21.4x 46.9x
Revenue Growth YoY +1.3% +65.5%
Gross Margin 81.5% 71.1%
Operating Margin 41.2% 60.4%
Return on Equity 34.7% 76.3%
Dividend Yield 3.1% 0.02%
FCF Yield 4.7% 2.13%
Analyst Consensus Buy Strong Buy
Investment Thesis
MRK โ€” Merck & Co., Inc.
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7โ€ฆ
NVDA โ€” NVIDIA Corporation
NVIDIA is the foundational infrastructure layer of the AI era. Data Center revenue reached $193.7B in FY2026, up 66% YoY, powered by insatiable demand for Blackwell B200 GPUs across hyperscalers and sovereign AI programs. The company generates $96.7B in annual free cash flow with 71% gross margins and 56% net margins, making it the most profitable semiconductor business in history. At P/E 37.7x vโ€ฆ
Accumulation Zones
Metric MRK NVDA
Zone Low $88.00 $218.00
Zone High $100.00 $250.00
In Buy Zone? No Yes
โ† MRK Research    NVDA Research โ†’    All Research